---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-167089"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:47:34.433906+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Ikena completes reverse merger with Inmagene, becomes ImageneBio; focuses on IMG-007 for atopic dermatitis

## Summary
- Merger closed July 25: Ikena acquired Inmagene, name changed to ImageneBio, ticker changes to IMA on Nasdaq Capital Market.
- Reverse stock split 1-for-12; post-merger shares ~11.2M; pre-merger Inmagene holders get ~43.5% of combined co.
- Only clinical asset: IMG-007 (anti-OX40 mAb) in Phase 2b ADAPTIVE trial for atopic dermatitis; non-OX40 assets divested.
- CVR agreements provide contingent payments to legacy Ikena and Inmagene shareholders from future asset sales.
- PIPE investors own ~21.5%; Hutchmed license has up to $92.5M in development/regulatory milestones plus royalties.

## SEC filing metadata
- accession: 0001193125-25-167089
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 1.01, 3.02, 9.01, 5.02, 3.03, 5.01, 5.03, 5.06, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/0001193125-25-167089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/d66290d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-167089
- JSON: https://secwatch.observer/filing/0001193125-25-167089.json
- Plain text: https://secwatch.observer/filing/0001193125-25-167089.txt

## Key facts
- Governance Changes
  ImageneBio, Inc.: Company ceased to be a shell company as a result of the Merger.
  - Change: shell status
  source text: As a result of the Merger, the Company ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the closing of the Merger.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/0001193125-25-167089-index.htm
- M&A Transactions
  ImageneBio, Inc. underwent a change of control involving Inmagene Biopharmaceuticals for Each Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock (closed 2025-07-25).
  - Action: change of control
  - Counterparty: Inmagene Biopharmaceuticals
  - Consideration: Each Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock
  - Closing: 2025-07-25
  source text: Time were canceled and ceased to exist, and no consideration was delivered in exchange therefor, (b) each then-outstanding Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock, par value $0.001 per share (“ Ikena Common Stock ”) (such ratio, the “ Exchange Ratio ”) and (c) each then-outstanding option to purchase Inmagene
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/0001193125-25-167089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.